Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosacharride in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

Abstract: Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0.

Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.

Abstract: Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0.

Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

Abstract: Disclosed are magnetic nanoparticles and methods of using magnetic nanoparticles for selectively removing biologics, small molecules, analytes, ions, or other molecules of interest from liquids.

Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

Abstract: The invention relates to nanoparticles made from organometallic hybrid materials made from iron carboxylates, used for example as contrast agents. The particles can also be used for the encapsulation and vectoring of molecules of interest such as active3 pharmaceutical agents, cosmetically interesting compounds and markers. Apart from the intrinsic properties thereof for imaging, said nanoparticles give good results in terms of capacity for loading with medicaments and in biocompatibility.

Abstract: The invention provides an iron-carbohydrate complex compound which is characterized by a content of iron(II). The invention also provides processes for the preparation of the iron-carbohydrate complex compound and the use thereof for treatment of iron deficiency anaemias.

Abstract: The present invention refers to a method for making iron(III)gluconate complex, preferably alkali iron(III)gluconate complex. The method includes the following steps: (i) mixing a water soluble iron(III)salt in aqueous solution, simultaneously or in any desired sequence, with a member selected from gluconic acid, a water soluble salt of gluconic acid and combinations thereof, and a member selected from an alkali hydroxide, an alkali carbonate, an alkali hydrogen carbonate and combinations thereof, so that the reaction mixture has an acid value (pH-value) within the range of from 7.0 to 12, provided that when alkali hydroxide is used, gluconic acid or a water soluble salt of gluconic acid is provided at the beginning of the reaction or is added to the reaction mixture simultaneously with the alkali hydroxide; (ii) heating the reaction mixture until the iron(III)gluconate complex has formed; and (iii) adding an organic solvent which is miscible with water until the iron(III)gluconate complex is precipitated.

Abstract: Water-soluble metal ion affinity compounds and methods for using the same are provided. The subject compounds include an aspartate based metal chelating ligand bonded to a water-soluble polymeric substrate, where the ligand is complexed with a metal ion. In certain embodiments, the subject compounds further include a member of a signal producing system, e.g., a directly or an indirectly detectable label moiety. Also provided are water-insoluble supports having the subject compounds present on, e.g., immobilized on, at least one surface thereof. The subject compounds find use in a variety of different applications, including analyte detection and analyte purification applications.

Abstract: The present invention provides a process of preparing a novel carboxylic acid derivative of dextran. In particular, in the present invention, carboxylated dextran containing at least one carboxylic acid is reduced to remove all or substantially all reducing groups.

Abstract: An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide.

Abstract: In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average molecular weight of the resulting iron-dextran compound can be varied.

Abstract: An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90% by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10% by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide.

Abstract: The present invention provides a polysaccharide-magnetic metal oxide complex consisting of a polysaccharide derivative obtained by carboxyalkyl-etherifying and unsubstituted or substituted aminoalkyl-etherifying a polysaccharide (the above carboxy group and/or amino group may be of a salt form) and a magnetic metal oxide. The above complex has a slow blood clearance and a low toxicity and is useful as a nuclear magnetic resonance imaging contrast medium.

Abstract: In a process of producing a carboxypolysaccharide by oxidizing a polysaccharide in the presence of a ruthenium compound and an oxidizing agent, the expensive ruthenium is easily and efficiently recovered. Ruthenium dissolved in a reaction mixture after the oxidation of the polysaccharide is converted, after or without being subjected to a heat. treatment, to high oxidation sate, which is then recovered by the extraction with a water-insoluble organic solvent. The recovered ruthenium is reduced to low oxidation state and reused in a subsequent production of the carboxypolysaccharide.

Abstract: The present invention concerns the use of an adsorbent material modified with polynuclear metal oxyhydroxides for the selective elimination of inorganic phosphate from liquids, in particular from body fluids containing protein such as whole blood, plasma, liquid contents of the intestine as well as from dialysis fluid, as well as a process for the production of a pharmaceutical agent for oral application for the selective removal of inorganic phosphate in which an adsorbent material used according to the present invention, as such or pressed into powder form, is coated with a layer resistant to gastric acid or dispensed into an acid-resistant capsule. In order to selectively eliminate inorganic phosphate in an extracorporeal perfusion system, a body fluid such as whole blood or plasma is passed over one of the adsorbent materials.

Abstract: The present invention concerns the use of an adsorbent material modified with polynuclear metal oxyhydroxides for the selective elimination of inorganic phosphate from liquids, in particular from body fluids containing protein such as whole blood, plasma, liquid contents of the intestine as well as from dialysis fluid, as well as a process for the production of a pharmaceutical agent for oral application for the selective removal of inorganic phosphate in which an adsorbent material used according to the present invention, as such or pressed into powder form, is coated with a layer resistant to gastric acid or dispensed into an acid-resistant capsule. In order to selectively eliminate inorganic phosphate in an extracorporeal perfusion system, a body fluid such as whole blood or plasma is passed over one of the adsorbent materials.

Abstract: A process for the crystallization of an iron-dextran complex in readily-filterable form comprising adding slowly, with stirring, an acidified aqueous iron-dextran solution to a vessel containing a water miscible organic solvent such as methanol, as well as crystalline iron-dextran complexes so prepared.

Abstract: An oxidized complex comprising a water-soluble carboxypolysaccharide and magnetic iron oxide, which is characterized by being obtained by oxidizing a complex comprising a water-soluble carboxypolysaccharide and magnetic iron oxide. Said oxidized complex has very low toxicity, is very stable, exhibits little or no blood pressure-reducing action and has low platelets-aggregating action when administered directly into the blood vessels of animals, and is useful in medical fields such as contrast medium for magnetic resonance imaging, exothermic medium for hyperthermia and the like.

Abstract: There are provided paramagnetic compounds comprising a paramagnetic metal species chelated by a chelating moiety bound by an amide group to a linker group itself bound by an ester group to a macromolecule, wherein said linker group provides a carbon chain of at least 2 atoms between said amide group and said ester group. The novel compounds are particularly suitable as contrast agents, e.g. in magnetic resonance imaging.

Abstract: Polycyclic mutagens are removed from aqueous or organic solutions by contacting the solution with a grafted dextranomer adsorbent which contains hydroxypropyl groups covalently linked to a reactive phthalocyanine dye.

Abstract: The present invention includes an image-enhancing agent comprising a biodegradable, water-soluble polymer, synthetic or naturally derived and having repeating hydrophilic monomeric units with amino or hydroxyl groups. This agent also includes chelating agents comprising functional groups bound to an amino or bydroxyl group of the monomeric units. These chelating agents have a formation constant for divalent or trivalent metal cations of at least about 10.sup.8 at physiological temperature and pH. This image-enhancing agent is biodegradable to intermediary metabolites, excretable chelates, oligomers, monomers or combinations thereof of low toxicity.These image-enhancing agents may further comprise a paramagnetic metal ion for enhancement of the image arising from induced magnetic resonance signals.Images resulting from scanning of gamma particle emissions may be enhanced when the image-enhancing agent of the present invention comprise radioisotopic metal ions emitting gamma particles.

Abstract: The preparation and isolation of biodegradable superparamagnetic MR imaging contrast agents for the vascular compartment is described. These aggregates are comprised of individual biodegradable superparamagnetic metal oxide crystals which aggregates have an overall mean diameter less than about 4000 angstroms. The preferred vascular imaging contrast agent is comprised of aggregates of iron oxide crystals having an overall mean diameter less than about 500 angstroms. These contrast agents may be associated with a macromolecular species, which assist, among other things, in the preparation of these extremely small materials, and may be dispersed or dissolved in a physiologically acceptable medium. Preferred media also stabilize the materials against further aggregation even under harsh sterilization conditions.

Abstract: This invention provides particle compositions possessing ferromagnetic, paramagnetic or diamagnetic properties. The particles are especially useful when used in the disease diagnostic and treatment regimens as described in U.S. Pat. Nos. 4,106,448, 4,136,683 and 4,303,636.

Abstract: There is disclosed a diagnostic agent containing a non-radioactive paramagnetic metal species which agent comprises a physiologically tolerable, water-soluble, hydroxyl group-containing macromolecular product to which is chemically bound said metal species, said product consisting essentially of at least one polymeric or polymerized carbohydrate or polymerized sugar alcohol or derivative thereof.

Abstract: A paramagnetic metal species-containing diagnostic agent is disclosed which comprises a non-radioactive paramagnetic metal species and, as a carrier therefor, a physiologically tolerable, water-insoluble, hydroxyl group-containing, particulate macromolecular product consisting essentially of at least one polymeric or polymerized carbohydrate or polymerized sugar alcohol or derivative thereof.

Abstract: A water-soluble iron dextran having a high iron content is prepared by adding to an aqueous solution containing more than 200 mmol D-glucose per 1000 U.alpha.(1.fwdarw.6)-D-glucosyltransferase, at 265 to 310 K and a pH value of 4.5 to 8, an aqueous sucrose solution in a mole ratio of sucrose to glucose of from 2.0 to 5.0; separating, after the consumption of the sucrose, glucose, liberated fructose and undesired oligosaccharides; reacting the so-purified dextran, having an average molar mass of from 2000 to 4000, with freshly precipitated iron(III) hydroxide and, if desired, further purifying the same.Iron dextrans having an iron content of from 27 to 33 percent by weight and an average molar mass of the dextran component of from 2000 to 4000, may be prepared according to the process of the invention which can be used in the treatment of iron deficiency.

Abstract: A novel hexonic acid derivative of dextran and a complex thereof with ferric hydroxide which complex is stable and non-toxic and has a high iron content are obtained under carefully controlled conditions by reacting dextran having a molecular weight range between 2000 and 6000 with sodium chlorite; and then reacting with ferric hydroxide to produce the desired complex.

Abstract: A water-soluble iron dextran having a high iron content is prepared by adding to an aqueous solution containing more than 200 mmol D-glucose per 1000 U.alpha.(1.fwdarw.6)-D- glucosyltansferase, at 265 to 310K and a pH value of 4.5 to 8, an aqueous sucrose solution in a mole ratio of sucrose to glucose of from 2.0 to 5.0; separating, after the consumption of the sucrose, glucose, liberated fructose and undesired oligosaccharides; reacting the so-purified dextran, having an average molar mass of from 2000 to 4000, with freshly precipitated iron (III) hydroxide and, if desired, further purifying the same.Iron dextrans having an iron content of from 27 to 33 percent by weight and an average molar mass of the dextran component of from 2000 to 4000, may be prepared according to the process of the invention which can be used in the treatment of iron deficiency.

Abstract: This invention provides particle compositions possessing ferromagnetic, paramagnetic or diamagnetic properties. The particles are especially useful when used in the disease diagnostic and treatment regimens as described in U.S. Pat. Nos. 4,106,448, 4,136,683 and 4,303,636.

Abstract: A process for the production of iron(III)hydroxide/dextran complexes in which from 2.0 to 2.6 vals of carbonate are slowly added to an acid solution containing a partially depolymerized dextran having an average molecular weight of from 1000 to 10,000 and an iron(III)salt, from 50 to 100 kg of iron ions being used per 100 kg of dextran, after which an alkali metal hydroxide or ammonium hydroxide is added to the solution in such a quantity that, including the carbonate added, approximately 3 vals of anions are added until a pH value of no less about 10.5 is reached, the suspension formed is converted into a solution by heating and the solution is worked up in known manner.The invention also relates to sterile pharmaceutical solutions containing these complexes.

Abstract: A composition is provided for the treatment of deficiency state of iron and selenium in a mammal, which composition comprises a precipitate-free solution containing a deficiency-treating amount of an iron compound and a selenium compound, wherein the iron compound is ferric dextran, ferric polymaltose or the corresponding hydrolysates thereof, and the selenium compound is selenium dioxide or selenium selenite.

Abstract: The invention provides new glycoside derivatives of 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline, to the production thereof and to their use as biological antioxidants, to protect vitamin E-deficient animals and as growth promoting agents.

Abstract: The present invention relates to novel dextran derivatives having a plurality of carboxylic acid groups positioned upon intermediate glucose or glucopyranose units of the dextran polymer, and substances formed therefrom by complexing or chelation with colloidal ferric hydroxide to produce stable products of low intravenous toxicity and containing a relatively high iron content. It further relates to a process for producing said polycarboxylic acid compounds as well as the ferric hydroxide complexes described.

Abstract: An aqueous, biologically-compatible, reversible, oxygen-carrying system comprising a novel metallated porphine-carbohydrate-fatty acid complex, particularly a novel tetra-(p-carboxyphenyl)porphine-iron(II)-dextran-octanoate complex, useful as a synthetic respiratory pigment, and a method for preparing same. The complexes may be dissolved in a suitable electrolyte and used as a substitute for red blood cells.

Abstract: A process is disclosed for the preparation of a complex of an element in solution, said complex including the element and an organic complexing agent, which process comprises treating a gel precipitate containing the element and an organic complexing agent to redisperse the gel precipitate into solution.

Abstract: The present invention is directed to an iron complex used in treatment of iron-deficiency anemia. The complex is formed by reacting a reactive polyiron (III) olated compound with dextrin and at least one hydroxycarboxylic acid. A dextrin-hydroxycarboxylato-polyiron (III) olated complex is produced. The reaction product contains substantially no free iron. Iron concentration is between about 35 and 47%. The complex can be administered non-orally.The compound of the subject invention has advantages over prior art compounds. Specifically, the subject complex has a high iron content, is thermally stable, and can be preserved. It may be administered intravenously without accumulating in the blood of an animal or damaging its tissue. No serious side effects result from use of the subject complex.

Abstract: The present invention is directed to a process for preparing an iron complex with polymeric polyhydroxy compounds such as dextran, hydrogenated dextran, dextrin, carboxyalkyl dextran, carboxyalkyl cellulose, alginates and the like, and therapeutic preparations thereof. The invention also relates to the products obtained, and to their administration to warm-blooded mammals.

Abstract: A magnetic iron oxide-dextran complex. This novel compound can be produced by reacting an aqueous sol of magnetic iron oxide with dextran having an intrinsic viscosity of about 0.02 to about 0.5 at an elevated temperature in an aqueous medium, and is useful not only in pharmaceutical and medical fields as a hematinic medium, a radiopaque medium, a blood measuring agent, or a carrier for a medicinal substance, but also in wide range of other technological fields where its magnetic property can be utilized.